B-Cell Non-Hodgkin Lymphoma - Pipeline Review, H1 2014
出 版 商：Global Markets Direct
出版日期：2014/02/28
頁 數：174頁
文件格式：PDF
價 格：
USD 2,000 (Single-User License)
USD 4,000 (Multi-User License)
USD 6,000 (Global-User License)
USD 4,000 (Multi-User License)
USD 6,000 (Global-User License)
B-Cell Non-Hodgkin Lymphoma - Pipeline Review, H1 2014
Summary
Global Markets Direct’s, ‘B-Cell Non-Hodgkin Lymphoma - Pipeline Review, H1 2014’, provides an overview of the B-Cell Non-Hodgkin Lymphoma’s therapeutic pipeline.
This report provides comprehensive information on the therapeutic development for B-Cell Non-Hodgkin Lymphoma, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for B-Cell Non-Hodgkin Lymphoma and special features on late-stage and discontinued projects.
Global Markets Direct’s report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Direct’s proprietary databases, Company/University websites, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources, put together by Global Markets Direct’s team. Drug profiles/records featured in the report undergoes periodic updation following a stringent set of processes that ensures that all the profiles are updated with the latest set of information. Additionally, processes including live news & deals tracking, browser based alert-box and clinical trials registries tracking ensure that the most recent developments are captured on a real time basis.
The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products.
Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data for the indicated disease.
Scope
- The report provides a snapshot of the global therapeutic landscape of B-Cell Non-Hodgkin Lymphoma
- The report reviews key pipeline products under drug profile section which includes, product description, MoA and R&D brief, licensing and collaboration details & other developmental activities
- The report reviews key players involved in the therapeutics development for B-Cell Non-Hodgkin Lymphoma and enlists all their major and minor projects
- The report summarizes all the dormant and discontinued pipeline projects
- A review of the B-Cell Non-Hodgkin Lymphoma products under development by companies and universities/research institutes based on information derived from company and industry-specific sources
- Pipeline products coverage based on various stages of development ranging from pre-registration till discovery and undisclosed stages
- A detailed assessment of monotherapy and combination therapy pipeline projects
- Coverage of the B-Cell Non-Hodgkin Lymphoma pipeline on the basis of target, MoA, route of administration and molecule type
- Latest news and deals relating related to pipeline products
Reasons to buy
- Provides strategically significant competitor information, analysis, and insights to formulate effective R&D development strategies
- Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage
- Develop strategic initiatives by understanding the focus areas of leading companies
- Identify and understand important and diverse types of therapeutics under development for B-Cell Non-Hodgkin Lymphoma
- Plan mergers and acquisitions effectively by identifying key players of the most promising pipeline
- Devise corrective measures for pipeline projects by understanding B-Cell Non-Hodgkin Lymphoma pipeline depth and focus of Indication therapeutics
- Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope
- Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline
Summary
Global Markets Direct’s, ‘B-Cell Non-Hodgkin Lymphoma - Pipeline Review, H1 2014’, provides an overview of the B-Cell Non-Hodgkin Lymphoma’s therapeutic pipeline.
This report provides comprehensive information on the therapeutic development for B-Cell Non-Hodgkin Lymphoma, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for B-Cell Non-Hodgkin Lymphoma and special features on late-stage and discontinued projects.
Global Markets Direct’s report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Direct’s proprietary databases, Company/University websites, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources, put together by Global Markets Direct’s team. Drug profiles/records featured in the report undergoes periodic updation following a stringent set of processes that ensures that all the profiles are updated with the latest set of information. Additionally, processes including live news & deals tracking, browser based alert-box and clinical trials registries tracking ensure that the most recent developments are captured on a real time basis.
The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products.
Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data for the indicated disease.
Scope
- The report provides a snapshot of the global therapeutic landscape of B-Cell Non-Hodgkin Lymphoma
- The report reviews key pipeline products under drug profile section which includes, product description, MoA and R&D brief, licensing and collaboration details & other developmental activities
- The report reviews key players involved in the therapeutics development for B-Cell Non-Hodgkin Lymphoma and enlists all their major and minor projects
- The report summarizes all the dormant and discontinued pipeline projects
- A review of the B-Cell Non-Hodgkin Lymphoma products under development by companies and universities/research institutes based on information derived from company and industry-specific sources
- Pipeline products coverage based on various stages of development ranging from pre-registration till discovery and undisclosed stages
- A detailed assessment of monotherapy and combination therapy pipeline projects
- Coverage of the B-Cell Non-Hodgkin Lymphoma pipeline on the basis of target, MoA, route of administration and molecule type
- Latest news and deals relating related to pipeline products
Reasons to buy
- Provides strategically significant competitor information, analysis, and insights to formulate effective R&D development strategies
- Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage
- Develop strategic initiatives by understanding the focus areas of leading companies
- Identify and understand important and diverse types of therapeutics under development for B-Cell Non-Hodgkin Lymphoma
- Plan mergers and acquisitions effectively by identifying key players of the most promising pipeline
- Devise corrective measures for pipeline projects by understanding B-Cell Non-Hodgkin Lymphoma pipeline depth and focus of Indication therapeutics
- Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope
- Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline
Table of Contents
Table of Contents 2
List of Tables 7
List of Figures 8
Introduction 9
Global Markets Direct Report Coverage 9
B-Cell Non-Hodgkin Lymphoma Overview 10
Therapeutics Development 11
Pipeline Products for B-Cell Non-Hodgkin Lymphoma - Overview 11
Pipeline Products for B-Cell Non-Hodgkin Lymphoma - Comparative Analysis 12
B-Cell Non-Hodgkin Lymphoma - Therapeutics under Development by Companies 13
B-Cell Non-Hodgkin Lymphoma - Therapeutics under Investigation by Universities/Institutes 16
B-Cell Non-Hodgkin Lymphoma - Pipeline Products Glance 17
Late Stage Products 17
Clinical Stage Products 18
Early Stage Products 19
Unknown Stage Products 20
B-Cell Non-Hodgkin Lymphoma - Products under Development by Companies 21
B-Cell Non-Hodgkin Lymphoma - Products under Investigation by Universities/Institutes 23
B-Cell Non-Hodgkin Lymphoma - Companies Involved in Therapeutics Development 24
Bristol-Myers Squibb Company 24
Johnson & Johnson 25
Boehringer Ingelheim GmbH 26
Amgen Inc. 27
Sanofi 28
Seattle Genetics, Inc. 29
Genentech, Inc. 30
MedImmune, LLC 31
Merck & Co., Inc. 32
Millennium Pharmaceuticals, Inc. 33
Biocon Limited 34
Ono Pharmaceutical Co., Ltd. 35
Sandoz Inc. 36
Celgene Corporation 37
Incyte Corporation 38
Merck KGaA 39
Immunomedics, Inc. 40
Portola Pharmaceuticals, Inc. 41
Pharmacyclics, Inc. 42
Senesco Technologies, Inc. 43
Simcere Pharmaceutical Group 44
Spectrum Pharmaceuticals, Inc. 45
Abiogen Pharma S.p.A. 46
Provenance Biopharmaceuticals Corp. 47
LFB Biotechnologies, S.A.S 48
Areta International s.r.l. 49
Molecular Templates Inc. 50
Aprogen, Inc. 51
BioMedics Japan Inc. 52
Pharmapraxis 53
B-Cell Non-Hodgkin Lymphoma - Therapeutics Assessment 54
Assessment by Monotherapy Products 54
Assessment by Target 55
Assessment by Mechanism of Action 58
Assessment by Route of Administration 61
Assessment by Molecule Type 63
Drug Profiles 65
bendamustine hydrochloride - Drug Profile 65
Product Description 65
Mechanism of Action 65
R&D Progress 65
alisertib - Drug Profile 66
Product Description 66
Mechanism of Action 66
R&D Progress 66
SAR-3419 - Drug Profile 69
Product Description 69
Mechanism of Action 69
R&D Progress 69
pralatrexate - Drug Profile 71
Product Description 71
Mechanism of Action 71
R&D Progress 71
vorinostat - Drug Profile 74
Product Description 74
Mechanism of Action 74
R&D Progress 74
RG-7593 - Drug Profile 77
Product Description 77
Mechanism of Action 77
R&D Progress 77
RG-7596 - Drug Profile 79
Product Description 79
Mechanism of Action 79
R&D Progress 79
moxetumomab pasudotox - Drug Profile 81
Product Description 81
Mechanism of Action 81
R&D Progress 81
milatuzumab - Drug Profile 83
Product Description 83
Mechanism of Action 83
R&D Progress 83
BVX-20 - Drug Profile 85
Product Description 85
Mechanism of Action 85
R&D Progress 85
DI-Leu16-IL2 - Drug Profile 86
Product Description 86
Mechanism of Action 86
R&D Progress 86
SNS-01T - Drug Profile 87
Product Description 87
Mechanism of Action 87
R&D Progress 87
ublituximab - Drug Profile 89
Product Description 89
Mechanism of Action 89
R&D Progress 89
PRT-2070 - Drug Profile 91
Product Description 91
Mechanism of Action 91
R&D Progress 91
MDX-1203 - Drug Profile 92
Product Description 92
Mechanism of Action 92
R&D Progress 92
SGN-CD19A - Drug Profile 93
Product Description 93
Mechanism of Action 93
R&D Progress 93
ibrutinib - Drug Profile 94
Product Description 94
Mechanism of Action 94
R&D Progress 94
siltuximab - Drug Profile 98
Product Description 98
Mechanism of Action 98
R&D Progress 98
Combotox - Drug Profile 102
Product Description 102
Mechanism of Action 102
R&D Progress 102
urelumab - Drug Profile 103
Product Description 103
Mechanism of Action 103
R&D Progress 103
NSC-678515 - Drug Profile 105
Product Description 105
Mechanism of Action 105
R&D Progress 105
CC-292 - Drug Profile 106
Product Description 106
Mechanism of Action 106
R&D Progress 106
EMD-521873 - Drug Profile 108
Product Description 108
Mechanism of Action 108
R&D Progress 108
rituximab biosimilar - Drug Profile 109
Product Description 109
Mechanism of Action 109
R&D Progress 109
BI-836826 - Drug Profile 110
Product Description 110
Mechanism of Action 110
R&D Progress 110
ONO-4059 - Drug Profile 111
Product Description 111
Mechanism of Action 111
R&D Progress 111
Anti-CD19-CAR-Transduced T Cells - Drug Profile 112
Product Description 112
Mechanism of Action 112
R&D Progress 112
BM-ca - Drug Profile 113
Product Description 113
Mechanism of Action 113
R&D Progress 113
GDC-0853 - Drug Profile 114
Product Description 114
Mechanism of Action 114
R&D Progress 114
INCB-050465 - Drug Profile 115
Product Description 115
Mechanism of Action 115
R&D Progress 115
rituximab biosimilar - Drug Profile 116
Product Description 116
Mechanism of Action 116
R&D Progress 116
Recombinant Idiotypic VK3-20 Vaccine - Drug Profile 117
Product Description 117
Mechanism of Action 117
R&D Progress 117
MT-3724 - Drug Profile 118
Product Description 118
Mechanism of Action 118
R&D Progress 118
rituximab biosimilar - Drug Profile 120
Product Description 120
Mechanism of Action 120
R&D Progress 120
PLS-123 - Drug Profile 121
Product Description 121
Mechanism of Action 121
R&D Progress 121
ublituximab - Drug Profile 122
Product Description 122
Mechanism of Action 122
R&D Progress 122
rituximab biosimilar - Drug Profile 124
Product Description 124
Mechanism of Action 124
R&D Progress 124
B-Cell Non-Hodgkin Lymphoma - Recent Pipeline Updates 125
B-Cell Non-Hodgkin Lymphoma - Dormant Projects 159
B-Cell Non-Hodgkin Lymphoma - Discontinued Products 160
B-Cell Non-Hodgkin Lymphoma - Product Development Milestones 161
Featured News & Press Releases 161
Dec 30, 2013: NICE says yes to non-Hodgkin's lymphoma treatment in final draft guidance 161
Dec 10, 2013: Pharmacyclics Announces Data Presentations for Ibrutinib in B-Cell Malignancies 161
Dec 04, 2013: Cell Therapeutics and GKV-SV Reach Agreement on Pricing of PIXUVRI in Germany 166
Dec 04, 2013: Completion of Cohort 3 in Phase 1b/2a Study in Multiple Myeloma and Non-Hodgkins B-Cell Lymphoma 167
Oct 21, 2013: Cell Therapeutics Announces Results from Preclinical Study of Pixantrone presented at the AACR-NCI-EORTC Meeting 168
Oct 15, 2013: Second Draft NICE Guidance for Aggressive non-Hodgkin Lymphoma Treatment, PIXUVRI 169
Sep 17, 2013: FDA Approves Teva’s TREANDA Injection, a New Liquid Formulation 170
Sep 09, 2013: TG Therapeutics' Ublituximab Receives Orphan Drug Designation for the Treatment of Nodal Marginal Zone Lymphoma and Extranodal Marginal Zone Lymphoma 170
Jun 17, 2013: Cell Therapeutics Announces Results From Sub-set Analyses Of Data From Phase III EXTEND Clinical Trial Of Pixuvri 171
Jun 11, 2013: Cell Therapeutics To Present Data On Pixantrone For Treatment Of B-cell Non-Hodgkin Lymphoma At 18th Congress Of EHA Annual Meeting 172
Appendix 173
Methodology 173
Coverage 173
Secondary Research 173
Primary Research 173
Expert Panel Validation 173
Contact Us 174
Disclaimer 174
List of Tables
Number of Products under Development for B-Cell Non-Hodgkin Lymphoma, H1 2014 11
Number of Products under Development for B-Cell Non-Hodgkin Lymphoma - Comparative Analysis, H1 2014 12
Number of Products under Development by Companies, H1 2014 14
Number of Products under Development by Companies, H1 2014 (Contd..1) 15
Number of Products under Investigation by Universities/Institutes, H1 2014 16
Comparative Analysis by Late Stage Development, H1 2014 17
Comparative Analysis by Clinical Stage Development, H1 2014 18
Comparative Analysis by Early Stage Development, H1 2014 19
Comparative Analysis by Unknown Stage Development, H1 2014 20
Products under Development by Companies, H1 2014 21
Products under Development by Companies, H1 2014 (Contd..1) 22
Products under Investigation by Universities/Institutes, H1 2014 23
B-Cell Non-Hodgkin Lymphoma - Pipeline by Bristol-Myers Squibb Company, H1 2014 24
B-Cell Non-Hodgkin Lymphoma - Pipeline by Johnson & Johnson, H1 2014 25
B-Cell Non-Hodgkin Lymphoma - Pipeline by Boehringer Ingelheim GmbH, H1 2014 26
B-Cell Non-Hodgkin Lymphoma - Pipeline by Amgen Inc., H1 2014 27
B-Cell Non-Hodgkin Lymphoma - Pipeline by Sanofi, H1 2014 28
B-Cell Non-Hodgkin Lymphoma - Pipeline by Seattle Genetics, Inc., H1 2014 29
B-Cell Non-Hodgkin Lymphoma - Pipeline by Genentech, Inc., H1 2014 30
B-Cell Non-Hodgkin Lymphoma - Pipeline by MedImmune, LLC , H1 2014 31
B-Cell Non-Hodgkin Lymphoma - Pipeline by Merck & Co., Inc., H1 2014 32
B-Cell Non-Hodgkin Lymphoma - Pipeline by Millennium Pharmaceuticals, Inc., H1 2014 33
B-Cell Non-Hodgkin Lymphoma - Pipeline by Biocon Limited., H1 2014 34
B-Cell Non-Hodgkin Lymphoma - Pipeline by Ono Pharmaceutical Co., Ltd., H1 2014 35
B-Cell Non-Hodgkin Lymphoma - Pipeline by Sandoz Inc., H1 2014 36
B-Cell Non-Hodgkin Lymphoma - Pipeline by Celgene Corporation, H1 2014 37
B-Cell Non-Hodgkin Lymphoma - Pipeline by Incyte Corporation, H1 2014 38
B-Cell Non-Hodgkin Lymphoma - Pipeline by Merck KGaA, H1 2014 39
B-Cell Non-Hodgkin Lymphoma - Pipeline by Immunomedics, Inc., H1 2014 40
B-Cell Non-Hodgkin Lymphoma - Pipeline by Portola Pharmaceuticals, Inc., H1 2014 41
B-Cell Non-Hodgkin Lymphoma - Pipeline by Pharmacyclics, Inc., H1 2014 42
B-Cell Non-Hodgkin Lymphoma - Pipeline by Senesco Technologies, Inc., H1 2014 43
B-Cell Non-Hodgkin Lymphoma - Pipeline by Simcere Pharmaceutical Group, H1 2014 44
B-Cell Non-Hodgkin Lymphoma - Pipeline by Spectrum Pharmaceuticals, Inc., H1 2014 45
B-Cell Non-Hodgkin Lymphoma - Pipeline by Abiogen Pharma S.p.A., H1 2014 46
B-Cell Non-Hodgkin Lymphoma - Pipeline by Provenance Biopharmaceuticals Corp., H1 2014 47
B-Cell Non-Hodgkin Lymphoma - Pipeline by LFB Biotechnologies, S.A.S, H1 2014 48
B-Cell Non-Hodgkin Lymphoma - Pipeline by Areta International s.r.l., H1 2014 49
B-Cell Non-Hodgkin Lymphoma - Pipeline by Molecular Templates Inc., H1 2014 50
B-Cell Non-Hodgkin Lymphoma - Pipeline by Aprogen, Inc., H1 2014 51
B-Cell Non-Hodgkin Lymphoma - Pipeline by BioMedics Japan Inc., H1 2014 52
B-Cell Non-Hodgkin Lymphoma - Pipeline by Pharmapraxis, H1 2014 53
Assessment by Monotherapy Products, H1 2014 54
Number of Products by Stage and Target, H1 2014 57
Number of Products by Stage and Mechanism of Action, H1 2014 60
Number of Products by Stage and Route of Administration, H1 2014 62
Number of Products by Stage and Molecule Type, H1 2014 64
B-Cell Non-Hodgkin Lymphoma Therapeutics - Recent Pipeline Updates, H1 2014 125
B-Cell Non-Hodgkin Lymphoma - Dormant Projects, H1 2014 159
B-Cell Non-Hodgkin Lymphoma - Discontinued Products, H1 2014 160
List of Figures
Number of Products under Development for B-Cell Non-Hodgkin Lymphoma, H1 2014 11
Number of Products under Development for B-Cell Non-Hodgkin Lymphoma - Comparative Analysis, H1 2014 12
Number of Products under Development by Companies, H1 2014 13
Number of Products under Investigation by Universities/Institutes, H1 2014 16
Comparative Analysis by Clinical Stage Development, H1 2014 18
Comparative Analysis by Early Stage Products, H1 2014 19
Assessment by Monotherapy Products, H1 2014 54
Number of Products by Top 10 Target, H1 2014 55
Number of Products by Stage and Top 10 Target, H1 2014 56
Number of Products by Top 10 Mechanism of Action, H1 2014 58
Number of Products by Stage and Top 10 Mechanism of Action, H1 2014 59
Number of Products by Top 10 Route of Administration, H1 2014 61
Number of Products by Stage and Top 10 Route of Administration, H1 2014 62
Number of Products by Top 10 Molecule Type, H1 2014 63
Number of Products by Stage and Top 10 Molecule Type, H1 2014 64
Table of Contents 2
List of Tables 7
List of Figures 8
Introduction 9
Global Markets Direct Report Coverage 9
B-Cell Non-Hodgkin Lymphoma Overview 10
Therapeutics Development 11
Pipeline Products for B-Cell Non-Hodgkin Lymphoma - Overview 11
Pipeline Products for B-Cell Non-Hodgkin Lymphoma - Comparative Analysis 12
B-Cell Non-Hodgkin Lymphoma - Therapeutics under Development by Companies 13
B-Cell Non-Hodgkin Lymphoma - Therapeutics under Investigation by Universities/Institutes 16
B-Cell Non-Hodgkin Lymphoma - Pipeline Products Glance 17
Late Stage Products 17
Clinical Stage Products 18
Early Stage Products 19
Unknown Stage Products 20
B-Cell Non-Hodgkin Lymphoma - Products under Development by Companies 21
B-Cell Non-Hodgkin Lymphoma - Products under Investigation by Universities/Institutes 23
B-Cell Non-Hodgkin Lymphoma - Companies Involved in Therapeutics Development 24
Bristol-Myers Squibb Company 24
Johnson & Johnson 25
Boehringer Ingelheim GmbH 26
Amgen Inc. 27
Sanofi 28
Seattle Genetics, Inc. 29
Genentech, Inc. 30
MedImmune, LLC 31
Merck & Co., Inc. 32
Millennium Pharmaceuticals, Inc. 33
Biocon Limited 34
Ono Pharmaceutical Co., Ltd. 35
Sandoz Inc. 36
Celgene Corporation 37
Incyte Corporation 38
Merck KGaA 39
Immunomedics, Inc. 40
Portola Pharmaceuticals, Inc. 41
Pharmacyclics, Inc. 42
Senesco Technologies, Inc. 43
Simcere Pharmaceutical Group 44
Spectrum Pharmaceuticals, Inc. 45
Abiogen Pharma S.p.A. 46
Provenance Biopharmaceuticals Corp. 47
LFB Biotechnologies, S.A.S 48
Areta International s.r.l. 49
Molecular Templates Inc. 50
Aprogen, Inc. 51
BioMedics Japan Inc. 52
Pharmapraxis 53
B-Cell Non-Hodgkin Lymphoma - Therapeutics Assessment 54
Assessment by Monotherapy Products 54
Assessment by Target 55
Assessment by Mechanism of Action 58
Assessment by Route of Administration 61
Assessment by Molecule Type 63
Drug Profiles 65
bendamustine hydrochloride - Drug Profile 65
Product Description 65
Mechanism of Action 65
R&D Progress 65
alisertib - Drug Profile 66
Product Description 66
Mechanism of Action 66
R&D Progress 66
SAR-3419 - Drug Profile 69
Product Description 69
Mechanism of Action 69
R&D Progress 69
pralatrexate - Drug Profile 71
Product Description 71
Mechanism of Action 71
R&D Progress 71
vorinostat - Drug Profile 74
Product Description 74
Mechanism of Action 74
R&D Progress 74
RG-7593 - Drug Profile 77
Product Description 77
Mechanism of Action 77
R&D Progress 77
RG-7596 - Drug Profile 79
Product Description 79
Mechanism of Action 79
R&D Progress 79
moxetumomab pasudotox - Drug Profile 81
Product Description 81
Mechanism of Action 81
R&D Progress 81
milatuzumab - Drug Profile 83
Product Description 83
Mechanism of Action 83
R&D Progress 83
BVX-20 - Drug Profile 85
Product Description 85
Mechanism of Action 85
R&D Progress 85
DI-Leu16-IL2 - Drug Profile 86
Product Description 86
Mechanism of Action 86
R&D Progress 86
SNS-01T - Drug Profile 87
Product Description 87
Mechanism of Action 87
R&D Progress 87
ublituximab - Drug Profile 89
Product Description 89
Mechanism of Action 89
R&D Progress 89
PRT-2070 - Drug Profile 91
Product Description 91
Mechanism of Action 91
R&D Progress 91
MDX-1203 - Drug Profile 92
Product Description 92
Mechanism of Action 92
R&D Progress 92
SGN-CD19A - Drug Profile 93
Product Description 93
Mechanism of Action 93
R&D Progress 93
ibrutinib - Drug Profile 94
Product Description 94
Mechanism of Action 94
R&D Progress 94
siltuximab - Drug Profile 98
Product Description 98
Mechanism of Action 98
R&D Progress 98
Combotox - Drug Profile 102
Product Description 102
Mechanism of Action 102
R&D Progress 102
urelumab - Drug Profile 103
Product Description 103
Mechanism of Action 103
R&D Progress 103
NSC-678515 - Drug Profile 105
Product Description 105
Mechanism of Action 105
R&D Progress 105
CC-292 - Drug Profile 106
Product Description 106
Mechanism of Action 106
R&D Progress 106
EMD-521873 - Drug Profile 108
Product Description 108
Mechanism of Action 108
R&D Progress 108
rituximab biosimilar - Drug Profile 109
Product Description 109
Mechanism of Action 109
R&D Progress 109
BI-836826 - Drug Profile 110
Product Description 110
Mechanism of Action 110
R&D Progress 110
ONO-4059 - Drug Profile 111
Product Description 111
Mechanism of Action 111
R&D Progress 111
Anti-CD19-CAR-Transduced T Cells - Drug Profile 112
Product Description 112
Mechanism of Action 112
R&D Progress 112
BM-ca - Drug Profile 113
Product Description 113
Mechanism of Action 113
R&D Progress 113
GDC-0853 - Drug Profile 114
Product Description 114
Mechanism of Action 114
R&D Progress 114
INCB-050465 - Drug Profile 115
Product Description 115
Mechanism of Action 115
R&D Progress 115
rituximab biosimilar - Drug Profile 116
Product Description 116
Mechanism of Action 116
R&D Progress 116
Recombinant Idiotypic VK3-20 Vaccine - Drug Profile 117
Product Description 117
Mechanism of Action 117
R&D Progress 117
MT-3724 - Drug Profile 118
Product Description 118
Mechanism of Action 118
R&D Progress 118
rituximab biosimilar - Drug Profile 120
Product Description 120
Mechanism of Action 120
R&D Progress 120
PLS-123 - Drug Profile 121
Product Description 121
Mechanism of Action 121
R&D Progress 121
ublituximab - Drug Profile 122
Product Description 122
Mechanism of Action 122
R&D Progress 122
rituximab biosimilar - Drug Profile 124
Product Description 124
Mechanism of Action 124
R&D Progress 124
B-Cell Non-Hodgkin Lymphoma - Recent Pipeline Updates 125
B-Cell Non-Hodgkin Lymphoma - Dormant Projects 159
B-Cell Non-Hodgkin Lymphoma - Discontinued Products 160
B-Cell Non-Hodgkin Lymphoma - Product Development Milestones 161
Featured News & Press Releases 161
Dec 30, 2013: NICE says yes to non-Hodgkin's lymphoma treatment in final draft guidance 161
Dec 10, 2013: Pharmacyclics Announces Data Presentations for Ibrutinib in B-Cell Malignancies 161
Dec 04, 2013: Cell Therapeutics and GKV-SV Reach Agreement on Pricing of PIXUVRI in Germany 166
Dec 04, 2013: Completion of Cohort 3 in Phase 1b/2a Study in Multiple Myeloma and Non-Hodgkins B-Cell Lymphoma 167
Oct 21, 2013: Cell Therapeutics Announces Results from Preclinical Study of Pixantrone presented at the AACR-NCI-EORTC Meeting 168
Oct 15, 2013: Second Draft NICE Guidance for Aggressive non-Hodgkin Lymphoma Treatment, PIXUVRI 169
Sep 17, 2013: FDA Approves Teva’s TREANDA Injection, a New Liquid Formulation 170
Sep 09, 2013: TG Therapeutics' Ublituximab Receives Orphan Drug Designation for the Treatment of Nodal Marginal Zone Lymphoma and Extranodal Marginal Zone Lymphoma 170
Jun 17, 2013: Cell Therapeutics Announces Results From Sub-set Analyses Of Data From Phase III EXTEND Clinical Trial Of Pixuvri 171
Jun 11, 2013: Cell Therapeutics To Present Data On Pixantrone For Treatment Of B-cell Non-Hodgkin Lymphoma At 18th Congress Of EHA Annual Meeting 172
Appendix 173
Methodology 173
Coverage 173
Secondary Research 173
Primary Research 173
Expert Panel Validation 173
Contact Us 174
Disclaimer 174
List of Tables
Number of Products under Development for B-Cell Non-Hodgkin Lymphoma, H1 2014 11
Number of Products under Development for B-Cell Non-Hodgkin Lymphoma - Comparative Analysis, H1 2014 12
Number of Products under Development by Companies, H1 2014 14
Number of Products under Development by Companies, H1 2014 (Contd..1) 15
Number of Products under Investigation by Universities/Institutes, H1 2014 16
Comparative Analysis by Late Stage Development, H1 2014 17
Comparative Analysis by Clinical Stage Development, H1 2014 18
Comparative Analysis by Early Stage Development, H1 2014 19
Comparative Analysis by Unknown Stage Development, H1 2014 20
Products under Development by Companies, H1 2014 21
Products under Development by Companies, H1 2014 (Contd..1) 22
Products under Investigation by Universities/Institutes, H1 2014 23
B-Cell Non-Hodgkin Lymphoma - Pipeline by Bristol-Myers Squibb Company, H1 2014 24
B-Cell Non-Hodgkin Lymphoma - Pipeline by Johnson & Johnson, H1 2014 25
B-Cell Non-Hodgkin Lymphoma - Pipeline by Boehringer Ingelheim GmbH, H1 2014 26
B-Cell Non-Hodgkin Lymphoma - Pipeline by Amgen Inc., H1 2014 27
B-Cell Non-Hodgkin Lymphoma - Pipeline by Sanofi, H1 2014 28
B-Cell Non-Hodgkin Lymphoma - Pipeline by Seattle Genetics, Inc., H1 2014 29
B-Cell Non-Hodgkin Lymphoma - Pipeline by Genentech, Inc., H1 2014 30
B-Cell Non-Hodgkin Lymphoma - Pipeline by MedImmune, LLC , H1 2014 31
B-Cell Non-Hodgkin Lymphoma - Pipeline by Merck & Co., Inc., H1 2014 32
B-Cell Non-Hodgkin Lymphoma - Pipeline by Millennium Pharmaceuticals, Inc., H1 2014 33
B-Cell Non-Hodgkin Lymphoma - Pipeline by Biocon Limited., H1 2014 34
B-Cell Non-Hodgkin Lymphoma - Pipeline by Ono Pharmaceutical Co., Ltd., H1 2014 35
B-Cell Non-Hodgkin Lymphoma - Pipeline by Sandoz Inc., H1 2014 36
B-Cell Non-Hodgkin Lymphoma - Pipeline by Celgene Corporation, H1 2014 37
B-Cell Non-Hodgkin Lymphoma - Pipeline by Incyte Corporation, H1 2014 38
B-Cell Non-Hodgkin Lymphoma - Pipeline by Merck KGaA, H1 2014 39
B-Cell Non-Hodgkin Lymphoma - Pipeline by Immunomedics, Inc., H1 2014 40
B-Cell Non-Hodgkin Lymphoma - Pipeline by Portola Pharmaceuticals, Inc., H1 2014 41
B-Cell Non-Hodgkin Lymphoma - Pipeline by Pharmacyclics, Inc., H1 2014 42
B-Cell Non-Hodgkin Lymphoma - Pipeline by Senesco Technologies, Inc., H1 2014 43
B-Cell Non-Hodgkin Lymphoma - Pipeline by Simcere Pharmaceutical Group, H1 2014 44
B-Cell Non-Hodgkin Lymphoma - Pipeline by Spectrum Pharmaceuticals, Inc., H1 2014 45
B-Cell Non-Hodgkin Lymphoma - Pipeline by Abiogen Pharma S.p.A., H1 2014 46
B-Cell Non-Hodgkin Lymphoma - Pipeline by Provenance Biopharmaceuticals Corp., H1 2014 47
B-Cell Non-Hodgkin Lymphoma - Pipeline by LFB Biotechnologies, S.A.S, H1 2014 48
B-Cell Non-Hodgkin Lymphoma - Pipeline by Areta International s.r.l., H1 2014 49
B-Cell Non-Hodgkin Lymphoma - Pipeline by Molecular Templates Inc., H1 2014 50
B-Cell Non-Hodgkin Lymphoma - Pipeline by Aprogen, Inc., H1 2014 51
B-Cell Non-Hodgkin Lymphoma - Pipeline by BioMedics Japan Inc., H1 2014 52
B-Cell Non-Hodgkin Lymphoma - Pipeline by Pharmapraxis, H1 2014 53
Assessment by Monotherapy Products, H1 2014 54
Number of Products by Stage and Target, H1 2014 57
Number of Products by Stage and Mechanism of Action, H1 2014 60
Number of Products by Stage and Route of Administration, H1 2014 62
Number of Products by Stage and Molecule Type, H1 2014 64
B-Cell Non-Hodgkin Lymphoma Therapeutics - Recent Pipeline Updates, H1 2014 125
B-Cell Non-Hodgkin Lymphoma - Dormant Projects, H1 2014 159
B-Cell Non-Hodgkin Lymphoma - Discontinued Products, H1 2014 160
List of Figures
Number of Products under Development for B-Cell Non-Hodgkin Lymphoma, H1 2014 11
Number of Products under Development for B-Cell Non-Hodgkin Lymphoma - Comparative Analysis, H1 2014 12
Number of Products under Development by Companies, H1 2014 13
Number of Products under Investigation by Universities/Institutes, H1 2014 16
Comparative Analysis by Clinical Stage Development, H1 2014 18
Comparative Analysis by Early Stage Products, H1 2014 19
Assessment by Monotherapy Products, H1 2014 54
Number of Products by Top 10 Target, H1 2014 55
Number of Products by Stage and Top 10 Target, H1 2014 56
Number of Products by Top 10 Mechanism of Action, H1 2014 58
Number of Products by Stage and Top 10 Mechanism of Action, H1 2014 59
Number of Products by Top 10 Route of Administration, H1 2014 61
Number of Products by Stage and Top 10 Route of Administration, H1 2014 62
Number of Products by Top 10 Molecule Type, H1 2014 63
Number of Products by Stage and Top 10 Molecule Type, H1 2014 64
